Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
Recruiting · NCT07536841 · Observational (researchers observe without assigning treatment) · Lead sponsor: Military Medical Clinical Center of the Southern Region, Ukraine
View the official record on ClinicalTrials.gov →Interventions studied
No intervention (observational study)
What this trial is about
This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.
- Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring.
- Ability to provide informed consent (for prospective participants).
Exclusion criteria
- Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology).
- Incomplete diagnostic data preventing OC26 scoring.
- Prior pancreatic surgery altering diagnostic interpretation.
Where it is running
2 locations listed.
- Military Medical Clinical Center of the Southern Region - Odesa, Ukraine
- Military Medical Clinical Center of the Southern Region - Odesa, Ukraine